|
|
|
| Neosil
Neosil is a privately-held dermatology-focused
specialty pharmaceutical company with several products
in pre-clinical development. The company’s core
topical anti-infective technology provides broad anti-microbial
activity, long duration of activity, and excellent formulation
flexibility. The technology is based on the work of
polymer chemist Dr. Samuel P. Sawan, a Professor in
the Department of Chemistry at the University of Massachusetts,
Lowell. Neosil was incubated and initially funded by
Shalon Ventures with follow-on financing provided by
MPM Capital (www.mpmcapital.com) and Burrill and Co.
(www.burrillandco.com). |
| |
|
 |
| OsteoGenix
Osteogenix is a therapeutic products company with novel products for the large and rapidly growing area of bone repair and bone growth. Osteogenix was founded in 2005 to clinically develop and commercialize the osteo-pharmacologic platform discovered and patented by Dr. Mundy and his associates. Osteogenix assembled an outstanding team of expert advisors, many of whom have been principal investigators in key orthobiologics trials. |
| |
|
 |
|
iWhisper is an excess weight reduction
company, developing a discreet, lightweight, and wearable
device that helps users lose weight and keep it off.
iWhisper monitors how users actually eat – notably
the timing, duration, and speed of eating – and
provides real-time feedback to help them change their
eating habits. The device is connected to the iWhisper
Network, which tracks progress and enables the user
and device to automatically communicate with their clinician
or peer group, thereby increasing compliance and efficacy.
Completely noninvasive and easy to use, iWhisper represents
a revolutionary and disruptive approach to the treatment
of obesity, one of the largest unsolved medical problems
today. |
| |
|
|
|
AirXpanders
AirXpanders is developing a next generation
tissue expansion platform for use in reconstructive
surgery and burn treatment. AirXpanders was co-founded
by Dr. Dan Jacobs, a leading reconstructive surgeon
at Kaiser Permanente in the San Francisco Bay Area.
Dr. Jacobs brought to Shalon Ventures his desire for
a more effective and more automated tissue expander.
Shalon Ventures provided the technical and business
know-how to address this unmet medical need.
|
| |
|
|
| Synteni
Synteni pioneered the use of DNA microarrays
for the genomic revolution. Starting with an academic
research project, Shalon Ventures developed Synteni
into one of the leading genomic players and service
providers in four years. Two years after its founding,
Shalon Ventures obtained follow-on funding for Synteni
from Kleiner Perkins Caulfield and Byers (www.kpcb.com),
with Brook Byers joining the Synteni Board of Directors.
Synteni was acquired in 1999 by Incyte (NASDAQ: INCY). |
| |
|
| |
BioPolymerix
In collaboration with Sam Sawan
PhD, a Professor of Chemistry at the University
of Massachusetts, BioPolymerix developed a silver-based
antimicrobial coating for medical applications.
These proprietary coatings prevent infection
and biofilm formation on a wide range of implantable
medical devices. BioPolymerix was acquired by
Biocompatibles International.
|
|
|
|
|
|
Intelligent Biocides
Using BioPolymerix’s silver technology
platform, Intelligent Biocides developed a broad set
of anti-microbial products for the consumer industry.
|
|
|
|
|
 |
